#USA #Indianapolis #Zepbound #Eli Lilly #Foundayo

Innovative Weight Management Strategies

Eli Lilly and Company has recently unveiled promising results from two late-phase trials, showcasing the effectiveness of its treatments, Foundayo and Zepbound, in sustaining weight loss over extended periods. These results are particularly significant for individuals transitioning from higher doses of injectable incretin therapy to these innovative solutions.

Trial Highlights

The trials, known as ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, concentrated on the long-term maintenance of weight loss. Participants who switched from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo successfully kept nearly all of their achieved weight loss, averaging just a 0.9 kg increase after one year. Similarly, those who decreased their dosage of Zepbound to 5 mg maintained all but 5.6 kg of weight loss over the same timeframe. Notably, participants sticking with the MTD of Zepbound for an additional year maintained all previous weight loss averages.

Dr. Louis J. Aronne, a recognized obesity specialist and consultant for Lilly, emphasized the ongoing challenge of weight regain in obesity management, attributing it to treatment interruptions that can impact biological processes adversely. He advocates for the use of these new medications as long-term solutions that can help maintain weight loss.

Study Results

SURMOUNT-MAINTAIN Findings

In the SURMOUNT-MAINTAIN trial, both Zepbound MTD and the reduced Zepbound 5 mg adhered to the primary and key secondary endpoints, confirming the safety and efficacy of Zepbound after the initial 60-week course of treatment. The participants who continued on Zepbound MTD witnessed an impressive average weight retention, maintaining all previous losses. Meanwhile, the group that transitioned to Zepbound 5 mg recorded an average retention of 5.6 kg, underscoring the effectiveness of this lower dosage in facilitating weight management.

Weight Maintenance Data: SURMOUNT-MAINTAIN

• - Zepbound MTD to Zepbound MTD

- Initial Average Body Weight: 112.2 kg (247.4 lbs)
- Weight After 60 Weeks: 89.5 kg (197.3 lbs)
- Maintenance Weight at Week 52: 88.7 kg (195.6 lbs)

• - Zepbound MTD to Zepbound 5 mg

- Initial Average Body Weight: 113.4 kg (250.0 lbs)
- Weight After 60 Weeks: 89.0 kg (196.2 lbs)
- Maintenance Weight at Week 52: 94.6 kg (208.6 lbs)

ATTAIN-MAINTAIN Findings

The ATTAIN-MAINTAIN trial further solidified the position of Foundayo as a robust option for weight maintenance. Participants who transitioned from Wegovy MTD to Foundayo retained nearly all weight loss, averaging just a 0.9 kg increase after one year of oral maintenance, while those switched from Zepbound MTD to Foundayo maintained an average of 5.0 kg.

Weight Maintenance Data: ATTAIN-MAINTAIN

• - Wegovy to Foundayo

- Initial Body Weight: 113.5 kg (250.2 lbs)
- Weight at Switch to Foundayo: 95.0 kg (209.4 lbs)
- Average Weight after 52 Weeks: 95.9 kg (211.4 lbs)

• - Zepbound to Foundayo

- Initial Body Weight: 115.8 kg (255.3 lbs)
- Weight at Switch to Foundayo: 90.9 kg (200.4 lbs)
- Average Weight after 52 Weeks: 95.9 kg (211.4 lbs)

Safety Profiles

Both Foundayo and Zepbound exhibited safety profiles consistent with previous Phase 3 studies, with common side effects including nausea, constipation, and gastrointestinal discomfort. The discontinuation rates due to adverse events were minimal across the trials, indicating a favorable tolerability profile for these medications.

Dr. Kenneth Custer, Lilly's EVP and president of Cardiometabolic Health, reiterated the importance of providing diverse treatment options in the management of obesity, highlighting that the results signal progress in addressing the long-term needs of patients.

Conclusion

Lilly's commitment to combating obesity through innovative therapies continues to yield promising outcomes, as illustrated by the latest trial results for Foundayo and Zepbound. These advancements not only represent a significant step towards effective long-term weight management but also reflect Lilly's dedication to enhancing the quality of life for individuals battling obesity.

For more information about these medications and ongoing research initiatives, visit Lilly's official website.